Paper Details

  1. Home
  2. Paper Details

[Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland].

Author: BellaicheY, HuberS, KapposL, Lechner-ScottJ, SpycherM, SteckA J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Recombinant interferon beta-1b was well-tolerated in patients with multiple sclerosis. The most common side effects were injection site reactions, flu-like symptoms, and fatigue. Treatment resulted in a 49% reduction in exacerbation rate.
Paper Details　
Original Abstract of the Article :
Recombinant interferon beta-1b has been registered with the Swiss health authorities since August 1995. Due to a special arrangement with health insurances it has been possible to prescribe this medication since spring 1995. We report on our experience with the first 30 consecutively treated multipl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8927950

データ提供：米国国立医学図書館（NLM）

Recombinant Beta-1b Interferon: A New Treatment for Multiple Sclerosis

This study evaluates the effectiveness of recombinant interferon beta-1b in treating multiple sclerosis (MS), a debilitating autoimmune disease. The researchers used a [研究手法] approach to assess the clinical response and safety profile of this novel treatment. The study revealed [主要な発見] about the impact of recombinant interferon beta-1b on MS patients, demonstrating its potential as a therapeutic agent. Notably, the researchers observed [特筆すべき結果や意義] in the treated patients, suggesting that recombinant interferon beta-1b might offer a significant therapeutic benefit for individuals with MS.

Recombinant Interferon Beta-1b: A Promising Treatment for Multiple Sclerosis

This research provides evidence for the efficacy of recombinant interferon beta-1b in treating multiple sclerosis. The observed [研究結果] suggests that this therapy could offer a valuable treatment option for individuals with MS. The study's findings contribute to the growing body of knowledge regarding effective therapies for this complex neurological disease.

Navigating the Challenges of Multiple Sclerosis

This research highlights the need for continued research into effective therapies for managing multiple sclerosis. The study emphasizes the importance of [日常生活で気をつけるべきことや取り入れるべきこと] for individuals with MS. By promoting awareness and encouraging early diagnosis, we can support patients in effectively managing their condition and improving their quality of life.

Dr. Camel's Conclusion

Just as a camel navigates a winding desert path, scientists are constantly searching for new routes to effectively treat multiple sclerosis. This study offers a promising glimpse into the potential of recombinant interferon beta-1b, providing hope for individuals facing this challenging condition. We must continue to journey forward, seeking innovative solutions and supporting those who are navigating the complexities of MS.
Date :
  1. Date Completed 1996-10-31
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

8927950

DOI: Digital Object Identifier

8927950

Related Literature

Article Analysis
・Side Effects of interferon beta-1b injection
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.